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Abstract 
Aims To undertake an individual patient data (IPD) meta-analysis to assess the impact of exercise-
based cardiac rehabilitation (ExCR) in patients with heart failure (HF) on mortality and 
hospitalisation, and differential effects of ExCR according to patient characteristics: age, sex, 
ethnicity, New York Heart Association (NYHA) functional class, ischaemic aetiology, ejection fraction, 
and exercise capacity. 
Methods Randomised trials of exercise training for at least 3 weeks compared with no exercise 
control with 6-months’ follow up or longer, providing IPD time to event on mortality or 
hospitalisation (all-cause or HF-specific). IPD were combined into a single dataset. We used Cox 
proportional hazards models to investigate the effect of ExCR and the interactions between ExCR 
and participant characteristics. We used both two-stage random effects, and 1-stage fixed effect, 
models. 
Results IPD was obtained from 18 trials including 3912 patients with reduced ejection fraction HF. 
Compared to control, there was no statistically significant difference in pooled time to event 
estimates in favour of ExCR although confidence intervals were wide: all-cause mortality: hazard 
ratio (HR): 0.83 (95% confidence interval (CI): 0.67 to 1.04), HF-related mortality: HR 0.84 (95% CI: 
0.49 to 1.46), all-cause hospitalisation: HR 0.90 (95% CI: 0.76 to 1.06), and HF-related hospitalisation: 
HR 0.98 (95% CI: 0.72 to 1.35). No strong evidence was found of differential intervention effects 
across patient characteristics. 
Conclusion ExCR did not have a statistically significant effect on the risk of mortality and 
hospitalisation in reduced ejection fraction HF. However, uncertainty around effect estimates 
precludes drawing definitive conclusions.  
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Introduction 
With increasing numbers of people living longer with symptomatic heart failure (HF), the 
effectiveness and accessibility of health services for HF patients have never been more important. 
Exercise-based cardiac rehabilitation (ExCR) is recognised as integral to the comprehensive care of 
HF patients.1,2 Cardiac rehabilitation is a process by which patients, in partnership with health 
professionals, are encouraged and supported to achieve and maintain optimal physical health.2 
Exercise training is at the centre of rehabilitation provision for HF. In addition, it is now accepted 
that programmes should be comprehensive in nature and also include education and psychological 
care, as well as focus on health and life-style behaviour change and psychosocial wellbeing.2,3  
 
Systematic reviews have shown ExCR offers important health benefits for HF patients.4-7 The 2014 
Cochrane review, based on aggregate trial data up to 12-months follow up, reported a reduction in 
the risk of overall hospitalisation (relative risk (RR) 0.75; 95% CI 0.62 to 0.92), HF-specific 
hospitalisation (RR 0.61; 95% CI 0.46 to 0.80) compared with no exercise control.7 However, there is 
uncertainty as to whether there are differential effects of ExCR across HF patient subgroups. In 2004, 
the Exercise Training Meta-Analysis of Trials for Chronic Heart Failure (ExTraMATCH) Collaborative 
Group published an individual patient data (IPD) meta-analysis based on 9 randomised trials in 801 
HF patients.8 ExTraMATCH reported a reduction in all-cause mortality (hazard ratio (HR): 0.65, 95% 
CI 0.46 to 0.92) and in the composite of mortality and hospital admission (HR 0.72, 95% CI 0.56 to 
0.93) with ExCR compared to no exercise control.  There were no statistically significant treatment 
effects across subgroups. Given the small number of trials, patients, and events, those subgroup 
analyses are likely to be underpowered. As the ExTraMATCH analysis did not take into account the 
cluster (or trial-level) nature of the data, it is likely to have underestimated the precision of the 
treatment effect. Since the ExTraMATCH analysis, there have been publications of trials of ExCR in 
HF, including HF-ACTION, a large US National Institute of Health funded trial with 2331 HF patients 
recruited from 82 centres.9  
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The ExTraMATCH II collaboration brings together the most comprehensive IPD meta-analysis of 
randomised trial data for ExCR in HF to date. Using contemporary IPD meta-analysis statistical 
methods, this study aimed to assess the impact of ExCR on the time to event outcomes (all-cause 
mortality, HF-specific mortality, all-cause hospital admission, and HF-specific hospital admission),  
and to identify subgroups of patients with HF that may respond differently to ExCR. 
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Methods 
This study was conducted and reported in accordance with current IPD guidance and Preferred 
Reporting Items for a Systematic Review and Meta-analysis of Individual Participant Data (PRISMA 
IPD) statement.10,11 The study was registered with the PROSPERO (CRD42014007170) and our full 
study protocol has been published elsewhere.12,13  
 
Search strategy and selection criteria  
Trials for inclusion were identified from the original ExTraMATCH IPD meta-analysis and the current 
Cochrane systematic review of ExCR for HF.7,8 The Cochrane review searched the following electronic 
databases: Cochrane Central Register of Controlled Trials (CENTRAL) in The Cochrane Library, 
EMBASE, MEDLINE, CINAHL, PsycINFO, and the NHS Centre for Reviews and Dissemination. 
Conference Proceedings were searched on Web of Science. Trial registers (Controlled-trials.com and 
Clinicaltrials.gov) and reference lists of all eligible trials and identified systematic reviews were also 
searched. No language limitations were imposed. Details of the search strategy used are reported in 
the study protocol.12  
Trials which met the following criteria were eligible for inclusion in this analysis: (i) randomised trials 
of adult patients (aged 18 years and older) with a diagnosis of HF with reduced ejection fraction 
(HFrEF) or HF with preserved ejection fraction (HFpEF) based on objective assessment of left 
ventricular ejection fraction and on clinical findings; (ii) trial intervention (ExCR) that included an 
aerobic exercise training component performed by the lower limbs, lasting a minimum of 3 weeks,7 
either alone or as part of a comprehensive cardiac rehabilitation programme which may also include 
health education and/or a psychological intervention; (iii) a control arm which did not prescribe an 
exercise intervention; (iv) a minimum follow-up of 6 months; and (v) a sample size of at least 50 (to 
ensure that the logistical effort in obtaining, cleaning and organising the data was commensurate 
with the contribution of the dataset to the analysis).14,15 
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Data management 
The principal investigators of included trials were invited by email to participate in this IPD meta-
analysis and share their anonymised trial data. Included datasets had ethical approval and consent 
from their sponsors. The complete list of all requested variables and details regarding collaboration 
with principal investigators are reported in the study protocol.12 Each dataset was saved in its 
original format and then converted and combined into one overall master dataset with standardised 
variables. All files are stored on a secure password protected computer server managed in 
accordance with the data management standard operating procedures of the nationally registered 
Exeter Clinical Trials Unit. Data from each trial were checked on range, extreme values, internal 
consistency, missing values, and consistency with published reports. Data discrepancies or missing 
information were discussed with trial investigators. Access to data at all stages of cleaning and 
analysis was restricted to core members of the research team (OC, RST, FCW, and SW). 
 
Specification of outcomes, subgroups, and risk of bias assessment  
We sought patient level time to event data from investigators for the following outcomes: time to 
all-cause and HF-specific mortality, and time to first all-cause and HF-specific hospitalisation. We also 
sought IPD on the following pre-defined patient characteristics: age, gender, ejection fraction, New 
York Heart Association (NYHA) functional class, HF aetiology (ischaemic or. non-ischaemic), ethnicity 
(white or other), and baseline (pre-randomisation) exercise capacity (e.g. peak oxygen uptake (VO2)). 
Study quality/risk of bias was assessed using the TESTEX quality assessment tool.16 
 
Statistical analysis 
A detailed statistical analysis plan was prepared (available from authors). All analyses were carried 
out according to the principle of intention to treat (i.e. patients included according to their 
randomised trial arm) and included only patients with   observed baseline data (where required) and 
outcome data at follow-up.  Where missing data was noted within an individual trial, contact with 
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the author was attempted and data added if available.  Given the relatively small levels of missing 
outcome and covariate data within trials, we did not undertake data imputation. We checked for 
potential small study bias by assessing funnel plot asymmetry and using the Egger test.22 
In the primary analysis, a two-stage approach was taken, with each trial first analysed using a Cox 
proportional hazards regression model and then trial-specific estimates of treatment effect (hazard 
ratio (HR)) or treatment–covariate interactions (HR of the interaction effect) were combined across 
trials using a random effects model. A random effects model was preferred due to the high degree 
of clinical heterogeneity across the individual trials, which included different patient populations, 
types of ExCR intervention, and comparators.17 The overall estimate of the effect of ExCR for each 
outcome, both by trial and as a pooled estimate, was presented as a HR and 95% confidence interval 
(CI). Additionally, the I2 and τ2 statistics were reported alongside the associated p-value for the 
results of the main analyses.  
Secondary analyses were based on a one-stage meta-analysis approach. Due to failure of 
convergence of one-stage random effects models, which was likely to be due to the low level of 
statistical heterogeneity between trials (indicated by the τ2 statistic), a fixed effect approach was 
used:  Cox regression models, stratified by trial. Stratification allowed the baseline hazard to vary 
between trials, rather than forcing the baseline hazards in individual trials to be proportionate to 
each other.19 To investigate subgroup effects, specifically interactions between ExCR effect and 
patient characteristics, we used the approach recommended by Riley et al.20 Continuous covariates 
were centred around the mean value within each trial; binary covariates were centred around the 
proportion within each trial. To present the results graphically, we performed individual subgroup 
one-stage fixed-effect IPD meta-analyses.  
To test the robustness of primary and secondary analyses, we undertook a number of pre-specified 
sensitivity analyses: (i) exclusion of the largest trial (HF-ACTION9); (ii) truncation of outcomes at 1-, 2- 
and 5-year follow-up. Small study effects were assessed for each outcome by funnel plot asymmetry 
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and using the Egger test.22 Results are reported as estimated HRs with 95% CIs. All analyses were 
undertaken using Stata 14.2 StataCorp LP, College Station, Texas, USA.  
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Results 
Study selection 
A total of 23 trials were deemed eligible for this IPD meta-analysis. Data from six trials have been 
analysed previously and were available from the ExTraMATCH database.23-28 We were unable to 
include data from three trials (355 patients); for two trials data were no longer available 29,30 and the 
investigators of the other trial could not be contacted.31 Of the remaining 17 trials, 14 investigators 
responded positively and shared their trial data. After obtaining IPD, one trial32 was excluded as it 
was determined that it included patient data that overlapped with another trial.33 A further trial was 
not included as insufficient data was provided to allow calculation of survival time or time to 
hospitalisation.34 This resulted in the inclusion of 18 trials comprising 3912 patients (1948 ExCR, 1964 
control) with a median follow-up of 19 months for mortality outcomes and 11 months for 
hospitalisation outcomes. Figure 1 summarises the study selection process. Full citations of included 
trials are included in eAppendix.e1-e18 
 
Characteristics of included trials and participants 
Patient baseline characteristics were well balanced between ExCR and control patients (see Table 1). 
The majority of patients were male (75%), with a mean age of 61 years (standard deviation (SD) 13). 
The mean baseline left-ventricular ejection fraction was 26.7% (SD 8.1%); no included trials recruited 
patients with preserved ejection fraction heart failure (ejection fraction >45%), and most patients 
were in NYHA functional class II (59%) or III (37%).  Trials from Europe and North America were 
published between 1990 and 2012 (see Table 2). Sample size ranged from 50 to 2130 patients. All 
trials evaluated an aerobic exercise intervention; six also included resistance training.e3,e4,e8,e9,e14,e15 
Exercise training was most commonly delivered in either an exclusively centre-based setting or a 
centre-based setting in combination with some home exercise sessions. Three trials were conducted 
in an exclusively home-based setting.e4,e9,e13 The dose of exercise training ranged widely across trials. 
ExCR was delivered over a period of 12 to 90 weeks, with between 2 and 7 sessions per week; 
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median session duration was between 15 and 120 minutes (including warm-up and cool-down). The 
intensity of exercise ranged between 50 to 85% peak VO2.  
 
Quality of included trials 
The overall quality of included trials was judged to be moderate to good, with a median TESTEX 
score of 11 (range 9 to 14) out of a maximum score of 15 (eTable1).  The criteria of allocation 
concealment and physical activity monitoring in the control groups were met in only three 
trials;e4,e7,e17  the other TESTEX criteria were met in 50% or more of trials.  
 
Effects of intervention on event outcomes 
Compared with control, ExCR did not have a statistically significant effect on mortality or 
hospitalisation. However, all time to event pooled treatment effects from random effects two-stage 
IPD meta-analysis were in favour of ExCR but with wide confidence intervals; all-cause mortality: HR 
0.83 (95% CI 0.67 to 1.04), p=0.107, 17 trials, 3782 patients, I2 =26%, τ2=0.04; HF-specific mortality: 
HR 0.84 (95% CI 0.49 to 1.46), p=0.527, 9 trials, 915 patients, I2 =0%, τ2=0.00; all-cause 
hospitalisation: HR 0.90 (95% CI 0.76 to 1.06), p=0.210, 11 trials, 3190 patients, I2 =12.4%, τ2=0.01; 
and HF-specific hospitalisation: HR 0.98 (95% CI 0.72 to 1.35), p=0.902, 13 trials, 3494 patients, I2 
=45%, τ2=0.10 (Figure 2a-d). These primary analysis results were broadly consistent across secondary 
and sensitivity analyses (eTables 2, 3, 4, and 5). Inferences did not change following the addition of 
trial level data from trials that met our study inclusion criteria but were not able to contribute IPD 
(data not shown here, available from authors). There was no evidence of significant small study bias 
for the four outcomes (eFigure 1).  
 
Differential treatment effects across patient characteristics (subgroups)Interaction analyses for the 
two-stage model revealed no consistent interactions between the effect of ExCR and any of the 
predefined subgroups (age, gender, ejection fraction, NYHA class, HF aetiology, ethnicity and 
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baseline peak VO2) for all-cause mortality, HF-related mortality, all-cause hospitalisation, or HF-
related hospitalisation. For comparison of mortality and hospitalisation rates within each subgroup, 
the HR and associated 95% CI from individual subgroup one-stage IPD meta-analyses are shown in 
Figures 3a-d, along with the p-value from the interaction test in the two-stage IPD meta-analyses. 
Some evidence of an interaction effect between ExCR and a patient characteristic (p<0.05) was seen 
in four sensitivity analyses (eTables 2, 3, 4, and 5): (i) ExCR was associated with a larger reduction in 
all-cause mortality in older patients (p=0.034) in the two-stage model with 2-year truncation; (ii) 
ExCR was associated with a larger reduction in HF-mortality  older patients (p=0.017) in the two-
stage model with 2-year truncation; (iii) ExCR was associated with a larger reduction in HF-mortality 
in ischemic patients (p=0.047) in the one-stage model without truncation; and (iv) ExCR was 
associated with a larger reduction in all-cause hospitalisation in patients with lower baseline peak 
VO2 (p=0.027) in the two-stage model with 1-year truncation.   
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Discussion 
Compared with no exercise control, ExCR did not have a statistically significant effect on mortality or 
hospitalisation in patients with reduced ejection fraction HF. Although we pooled IPD from 18 trials 
including 3912 patients, treatment effect estimates were imprecise. We found no strong evidence 
for a differential effect of ExCR according to patient characteristics.  
 
Unlike the previous IPD meta-analysis, ExTraMATCH8, our analyses did not show a definitive benefit 
of ExCR in terms of either time to all-cause death or all-cause hospitalisation. The confidence 
intervals around the effect of ExCR were wide and failed to reach statistical significance. The wide 
confidence intervals may be due to several factors, including: (i) variation in the ExCR intervention 
across trials; (ii) variation in adherence to ExCR within trials; (iii) variation in treatment effect of ExCR 
among adherent patients; and (iv) variation in the composition/effectiveness of usual care within 
and across trials. A potential explanation for this reduction in strength of effect of ExCR on clinical 
events could be due to improvements in rates of mortality and hospitalisation with time as a result 
of the inclusion of more recent trials in this updated IPD analysis. More recent trials are more likely 
to have utilised prognostic innovations in usual care treatments for HF, including devices 
(resynchronisation and defibrillator therapy) and disease modifying drugs (beta-blockers, ACE 
inhibitors, angiotensin II receptor antagonists, and mineralocorticoid receptor antagonists). 
However, the Cochrane systematic review of ExCR for HF showed that this may not be case. Meta-
regression showed no statistical association between trial publication date and the magnitude of 
ExCR effect on mortality or hospitalisation.11,35 This Cochrane analysis also showed no association 
between the magnitude of ExCR effect and trial setting (single or multicentre), type of CR 
(comprehensive versus exercise only), or ExCR dose.  
Our finding of a lack of consistent evidence of a beneficial effect of ExCR for any HF patient subgroup 
agrees with both the previous ExTraMATCH and Cochrane 2014 analyses..7,8 However, these two 
previous studies had major limitations that are likely to have limited their ability to detect subgroup 
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effects. ExTraMATCH included data on only 801 HF patients and observed 88 deaths and 300 
patients with a composite outcome of death or hospitalisation, and therefore lacked statistical 
power. Using meta-regression analysis, the 2014 Cochrane review found no association between 
trial level patient characteristics (age, gender, ejection fraction) and ExCR. However, meta-regression 
analysis is highly prone to study level confounding (ecological fallacy) and should be interpreted with 
great caution.36 Nevertheless, our findings are also consistent with the IPD subgroup interaction 
analyses from the multicentre HF-ACTION trial. The HF-ACTION investigators reported no significant 
interaction effect on their composite primary outcome (all-cause mortality or hospitalisation) 
between exercise training intervention and the subgroups of age (≤70 vs. > 70 years), gender, race 
(white vs. non-white), HF aetiology (ischaemic vs. non ischaemic), ejection fraction (≤25% vs. >25%), 
and NHYA class (II vs. III/IV).9,37 
 
Strengths and limitations 
Our ExTraMATCH II study has a number of strengths. We believe this to be the first IPD meta-
analysis including sufficiently large numbers of HF patients (3912) and events (701 all-cause deaths, 
1642 first all-cause hospitalisations) to be able to identify differential effects of ExCR in patients with 
different characteristics.  We were able to standardise the handling and analysis of time to event 
outcomes across trials. Our findings were broadly consistent across analytic approaches that 
included one-- and two-stage IPD meta-analysis models and a range of sensitivity analyses. Finally, 
we found no evidence of publication bias. Whilst systematic reviews and meta-analyses of IPD from 
randomised trials are recognised as the gold standard for assessing intervention effects,39 our study 
has a number of limitations. First and foremost, there was a lack consistency in how included trials 
with IPD in our analyses defined and collected clinical event outcome data. As noted in recent 
commentaries on clinical events in HF trials, with the exception of all-cause mortality, the collection 
and reporting the other outcomes including cause-specific mortality and hospitalisation can be 
prone to confounding and bias.39 We made considerable efforts to contact study authors in order to 
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clarify issues around the definition of hospitalisations and HF-specific deaths. Although we were able 
to resolve data issues in many cases, we recognise that a lack of consistency in outcome definition 
across included trials may exist, weakening the strength of our conclusions for these outcomes.  
Second, overall, IPD was available to ExTraMATCH II for 3912/4267 patients in 18/23 trials identified 
as eligible, equating to an omission of only 8% of all participants across all eligible trials. However, 
not all included trials collected IPD for the time to event outcomes or patient characteristics 
assessed in this study. The large multicentre HF-ACTION trial did not collect HF-specific 
hospitalisation, thus reducing our statistical power for this outcome. Although, across the trials that 
provided outcome data, the proportion of patients with missing clinical event or baseline covariate 
data was low, this may have introduced bias in our results. Finally, we did not have patient level data 
on ‘ExCR dose’, i.e. adherence to duration, frequency and intensity of ExCR undertaken by an 
individual patient. Using IPD from HF-ACTION, Keteyian et al found exercise volume (defined as 
metabolic equivalent of task (MET)-hour per week) to be a predictor for the composite outcome of 
all-cause mortality or hospitalisation (p=0.03).40 Whilst this analysis indicates that patient level ExCR 
‘dose’ is a key potential explanatory variable, this data was not available across the trials in our 
analyses.  
 
Implications for practice and further research 
In spite of the comprehensiveness of this IPD meta-analysis, findings of this study demonstrate that 
further evidence is still required to definitively assess the impact of ExCR on mortality and 
hospitalisation in patients with reduced ejection fraction HF; in particular, to increase the power to 
examine whether the effect of ExCR varies according to patient characteristics. To more reliably 
quantify the impact of ExCR on clinical outcomes and examine how these effects may vary across HF 
patients, there is an urgent need for trial investigators to more consistently collect, report, and share 
patient-level data in the future. Two central aspects of future data collection include a consensus on 
the definition, collection, and reporting of clinical event data, especially hospitalisation, plus the 
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capture of data on patient-level adherence to the amount of exercise training during the ExCR 
intervention period. Our forthcoming IPD meta-analysis will examine the impact of ExCR exercise 
capacity on health-related quality of life and explore how this treatment effect may vary across 
according to HF patient characteristics.12,13  
 
Conclusion 
ExCR did not significantly reduce the risk of mortality and hospitalisation in patients with reduced 
ejection fraction HF.   Although we pooled the IPD from a number of randomised trials, treatment 
effect estimates remain imprecise which precludes drawing definitive conclusions. To allow 
definitive assessment of the effect of ExCR for patients with HF, and to investigate differential 
treatment effects across specific patient characteristics, a consensus in trial methodology needs to 
be reached that will allow more detailed and consistently recorded IPD to be routinely collected 
from clinical trials in ExCR. 
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Table 1. Baseline characteristics of patients 
 Characteristic ExCR 
(n=1,948) 
Control 
(n=1,964) 
All  
(n=3,912) 
Age (years),  mean (SD) 61.3 (12.7) 61.4 (13.2) 61.3 (13.0) 
Gender  
   Male 
   Female 
 
1442 (74) 
506 (26) 
 
1489 (76) 
475 (24) 
 
2,931 (75) 
981 (25) 
Baseline ejection fraction 
(%); mean  (SD) 
26.8 (8.2) 26.7 (8.1) 26.7 (8.1) 
NYHA status  
   Class I 
   Class II 
   Class III 
   Class IV 
 
25 (1) 
1107 (59) 
700 (37) 
47 (3) 
 
28 (1) 
1130 (60) 
708 (37) 
26 (1) 
 
53 (1) 
2237 (59) 
1408 (37) 
73 (2) 
Aetiology  
   Ischaemic  
   Non-ischemic 
 
1094 (57) 
809 (43) 
 
1080 (56) 
838 (44) 
 
2174 (57) 
1647 (43) 
Ethnicity 
   White 
   Non-white 
 
1100 (70) 
472 (30) 
 
1140 (72) 
445 (28) 
 
2240 (71) 
917 (29) 
VO2 peak (ml/kg/min);  
mean (SD) 
14.9 (4.4) 15.0 (4.6) 14.9 (4.5) 
Data are n (%) unless otherwise indicated; percentages may not sum to 100 
because of rounding; NHYA: New York Heart Association; SD: standard deviation; 
VO2 peak: peak oxygen uptake. 
 
  
Table 2. Characteristics of included studies 
Study characteristics 
Publication year 
   1990 to 1999 
   2000 to 2009 
   2010 to 2012 
   Unpublished 
 
2 (11) 
12 (67) 
3 (17) 
1 (6) 
Main study location 
   Europe   
   North America* 
 
14 (78) 
4 (22) 
Single study centre 
   Single 
   Multiple  
   Not reported 
 
12 (67) 
5 (28) 
1 (6) 
Sample size 
   0 to 99 
   100 to 999 
   1000 and over 
 
10 (56) 
7 (39) 
1 (6) 
Duration of follow-up in dataset (months), median 
(range) 
   Mortality 
   Hospitalisation 
 
 
18.6 (11.8 to 419) 
11.2 (2.6 to 98) 
Intervention characteristics 
Intervention type 
   Exercise only programs 
   Comprehensive programs 
   Not reported 
 
5 (28) 
12 (67) 
1 (6) 
Type of exercise 
   Aerobic exercise only 
   Aerobic plus resistance training  
 
12 (67) 
6 (33) 
Dose of intervention  
   Duration of intervention (weeks), median (range) 
   Frequency (sessions per week), median (range) 
   Length of exercise session (mins), median (range) 
   Exercise intensity, range 
 
 
 
30 (15 to 90) 
2.8 (2 to 7) 
24 (15 to 120) 
40-80% maximum heart rate 
50-85% peak VO2 
12-18 Borg rating  
Setting 
   Centre-based only 
   Home-based only 
   Centre- and home-based 
   Not reported 
 
6 (33) 
3 (17) 
8 (44) 
1 (6) 
Data are n (%) unless otherwise indicated; percentages may not sum to 100 
because of rounding; *O’Connor study was categorised as North America but was 
also delivered in to a small number of patients in France 
 
 
  
Figure 2. Effect of ExCR on mortality and hospitalisation: two-stage IPD meta-
analysis 
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HR (95% CI) 
p-value 
Two-stage 
model,  
random 
effects 
excluding  
HF-Action 
HR (95% CI) 
p-value 
 
One-stage 
Cox model, 
stratified by 
study with 
fixed  
effect 
excluding  
HF-Action 
HR (95% CI) 
p-value 
Two-stage 
model,  
random 
effects 
1 year 
truncation 
HR (95% CI) 
p-value 
Two-stage 
model,  
random 
effects 
2 year 
truncation 
HR (95% CI) 
p-value 
Two-stage 
model,  
random 
effects 
5 year 
truncation 
HR (95% CI) 
p-value 
Overall effect 0.84 (0.67, 
1.04) 
p=0.107 
0.85 (0.73, 
0.99) 
p=0.034 
0.81 (0.61, 
1.06) 
p=0.129 
0.79 (0.64, 
0.97) 
p=0.027 
0.87 (0.58, 
1.31) 
p=0.507 
0.86 (0.67, 
1.10) 
p=0.217 
0.84 (0.66, 
1.06) p=0.140 
Interaction terms 
Age 
(years)* 
0.99 (0.98, 
1.00) 
p=0.165 
0.99 (0.98, 
1.01) 
p=0.254 
0.98 (0.96, 
1.01) 
p=0.144 
0.99 (0.96, 
1.01) 
p=0.228 
0.98 (0.95, 
1.00) 
p=0.077 
0.98 (0.96, 
1.00) 
p=0.034 
0.99 (0.97, 
1.00) 
p=0.097 
Gender 
(male vs 
female) 
1.10 (0.73, 
1.66) 
p=0.660 
1.06 (0.70, 
1.60) 
p=0.783 
0.71 (0.35, 
1.43) 
p=0.341 
0.70 (0.36, 
1.36) 
p=0.300 
0.76 (0.34, 
1.68) 
p=0.490 
0.96 (0.55, 
1.67) 
p=0.872 
1.17 (0.75, 
1.82) 
p=0.481 
Ejection 
fraction (%)* 
0.99 (0.97, 
1.01) 
p=0.250 
0.99 (0.97, 
1.01) 
p=0.332 
0.98 (0.95, 
1.01) 
p=0.124 
0.98 (0.96, 
1.01) 
p=0.201 
1.04 (1.00, 
1.08) 
p=0.055 
0.99 (0.97, 
1.02) 
p=0.688 
0.99 (0.97, 
1.01) 
p=0.506 
NYHA class  
(NYHA I/II vs 
NYHA III/IV) 
0.80 (0.58, 
1.11) 
p=0.182 
0.79 (0.57, 
1.08) 
p=0.134 
0.82 (0.49, 
1.38) 
p=0.459 
0.75 (0.46, 
1.22) 
p=0.244 
0.50 (0.23, 
1.07) 
p=0.073 
0.84 (0.54, 
1.30) p=0.431 
0.83 (0.59. 
1.18) 
p=0.297 
HF aetiology 
(ischaemic vs 
0.73 (0.38, 
1.39)  
1.19 (0.86, 
1.64)  
0.69 (0.36, 
1.31)  
0.87 (0.54, 
1.41) 
0.69 (0.19, 
2.54) 
0.79 (0.38, 
1.67)  
0.70 (0.33, 
1.47)  
non-
ischaemic) 
p=0.335 p=0.297 p=0.255 p=0.575 p=0.574 p=0.542 p=0.345 
Ethnic group  
(white vs non-
white) 
1.12 (0.74, 
1.69) 
p=0.593 
1.11 (0.74, 
1.68) 
p=0.604 
† 1.05 (0.25, 
4.31) 
p=0.949 
0.72 (0.34, 
1.53) 
p=0.396 
0.83 (0.50, 
1.38) 
p=0.468 
1.12 (0.74, 
1.69) 
p=0.593 
Exercise capacity       
Peak VO2 
directly 
measured* 
1.00 (0.95, 
1.05) 
p=0.937 
0.99 (0.95, 
1.04) 
p=0.783 
0.98 (0.90, 
1.08) 
p=0.712 
0.99 (0.91, 
1.07) 
p=0.777 
0.97 (0.88, 
1.06) 
p=0.456 
0.99 (0.93, 
1.05) 
p=0.780 
0.98 (0.91, 
1.06) 
p=0.630 
Peak VO2, 
directly 
measured and 
predicted* 
1.00 (0.95, 
1.06) 
p=0.903 
1.00 (0.96, 
1.04) 
p=0.954 
1.00 (0.91, 
1.08) 
p=0.923 
1.00 (0.93, 
1.07) 
p=0.984 
0.99 (0.90, 
1.08) 
p=0.734 
1.00 (0.94, 
1.06) 
p=0.961 
1.00 (0.93, 
1.07) 
p=0.924 
Standardised 
scores using 
peak VO2, 
6MWT, ISWT 
units, and 
watts* 
1.03 (0.83, 
1.27) 
p=0.802 
1.02 (0.85, 
1.22) 
p=0.851 
0.99 (0.71, 
1.39) 
p=0.955 
1.01 (0.75, 
1.35) 
p=0.967 
0.97 (0.66, 
1.41) 
p=0.858 
1.00 (0.78, 
1.30) 
p=0.972 
1.01 (0.76, 
1.35) 
p=0.938 
*centered; †Study estimate not available as too few studies provide data; peak VO2: peak oxygen uptake; ISWT: incremental 
shuttle walk test; 6MWT: 6-minute walk test. 
  
eTable 3. HF-specific mortality - overall treatment effect and subgroups effects^ 
 Primary 
analysis 
Secondary 
analysis 
Sensitivity analyses 
  Two-stage 
model,  
random effects 
HR (95% CI) 
p-value 
One-stage Cox 
model, 
stratified by study 
with fixed  
treatment effect 
HR (95% CI) 
p-value 
Two-stage model,  
random effects 
1 year truncation 
HR (95% CI) 
p-value  
Two-stage model,  
random effects 
2 year truncation 
HR (95% CI) 
p-value  
Two-stage model, 
random effects 
5 year truncation 
HR (95% CI) 
p-value 
Overall effect 0.84 (0.48, 1.46) 
p=0.527 
0.75 (0.44, 1.28) 
p=0.294 
† 1.30 (0.59, 2.87) 
p=0.515 
0.84 (0.49, 1.53) 
p=0.575 
Interaction terms 
Age (years)* 0.96 (0.91, 1.02) 
p=0.206 
0.96 (0.92, 1.01) 
p=0.162 
† 0.91 (0.84, 0.98) 
p=0.017 
0.95 (0.90, 1.00) 
p=0.066 
Gender (male vs 
female) 
0.53 (0.08, 3.73) 
p=0.524 
0.61 (0.11, 3.49) 
p=0.583 
† † † 
Ejection fraction 
(%)* 
0.95 (0.89, 1.02) 
p=0.159 
0.96 (0.90, 1.02) 
p=0.179 
† 1.01 (0.82, 1.24) 
p=0.912 
0.96 (0.89, 1.04) 
p=0.309 
NYHA class (NYHA 
I/II vs NYHA III/IV) 
0.54 (0.07, 4.28) 
p=0.562 
0.78 (0.23, 26.65) 
p=0.691 
† † 0.54 (0.07, 4.28) 
p=0.562 
HF aetiology 
(ischaemic vs non-
ischaemic) 
Data only 
available for one 
study 
3.30 (1.0102, 10.7) 
p=0.047 
† † † 
Ethnic group (white 
vs non-white) 
† † † † † 
Exercise capacity          
Peak VO2, directly 
measured* 
0.90 (0.76, 1.07) 
p=0.232 
0.93 (0.78, 1.09) 
p=0.362 
† 0.98 (0.73, 1.31) 
p=0.893 
0.86 (0.69, 1.06) 
p=0.146 
Peak VO2, directly 
measured and 
0.91 (0.77, 1.07) 
p=0.263 
0.94 (0.80, 1.10) 
p=0.423 
† 0.98 (0.76, 1.26) 
p=0.854 
0.88 (0.72, 1.06) 
p=0.184 
predicted* 
Standardised scores 
using peak VO2, 
6MWT, ISWT units 
and watts score 
0.69 (0.35, 1.35) 
p=0.276 
0.82 (0.43, 1.56) 
p=0.545 
† 0.86 (0.31, 2.37) 
p=0.773 
0.61 (0.28, 1.32) 
p=0.210 
^HF-Action did not provide HF-mortality so sensitivity analysis of omission not undertaken; *centered; † Study estimate not 
available as too few studies provide data; peak VO2: peak oxygen uptake; ISWT: incremental shuttle walk test; 6MWT: 6-minute 
walk test. 
 
  
eTable 4. All-cause hospitalisation - overall treatment effect and subgroups effects 
 Primary 
analysis 
Secondary 
analysis 
Sensitivity analyses 
  Two-stage 
model,  
random 
effects 
HR (95% CI) 
p-value 
One-stage 
Cox model, 
stratified by 
study with 
fixed  
treatment 
effect 
HR (95% CI) 
p-value 
Two-stage 
model,  
random 
effects 
excluding  
HF-Action 
HR (95% CI) 
p-value 
 
One-stage 
Cox model, 
stratified by 
study with 
fixed  
treatment 
effect 
excluding  
HF-Action 
HR (95% CI) 
p-value 
Two-stage 
model,  
random 
effects 
1 year 
truncation 
HR (95% CI) 
p-value  
Two-stage 
model,  
random 
effects 
2 year 
truncation 
HR (95% CI) 
p-value  
Two-stage 
model,  
random 
effects 
5 year 
truncation 
HR (95% CI) 
p-value  
Overall effect 0.90 (0.76, 
1.06) 
p=0.210 
0.91 (0.83, 
1.01) 
p=0.072 
0.86 (0.64, 
1.14) 
p=0.293 
0.85 (0.68, 
1.09) 
p=0.210 
0.94 (0.75, 
1.18) 
p=0.583 
0.91 (0.74, 
1.11) 
p=0.330 
0.90 (0.76, 
1.06) 
p=0.210 
Interaction terms 
Age (years)* 1.00 (0.99, 
1.01) 
p=0.794 
1.00 (0.99, 
1.01) 
p=0.854 
1.00 (0.98, 
1.03) 
p=0.808 
1.00 (0.98, 
1.02) 
p=-0.969 
1.00 (0.99, 
1.01) 
p=0.636 
1.00 (0.99, 
1.01) 
p=0.798 
1.00 (0.99, 
1.01)  
p=0.794 
Gender (male 
vs female) 
1.09 (0.87, 
1.36) 
p=0.454 
1.09 (0.88, 
1.36) 
p=0.424 
0.66 (0.38, 
1.14) 
p=0.136 
0.68 (0.39, 
1.16) 
p=0.158 
1.05 (0.80, 
1.37) 
p=0.745 
1.15 (0.91, 
1.46) 
p=0.239 
1.09 (0.87, 
1.35) 
p=0.454 
Ejection 
fraction (%)* 
1.00 (0.98, 
1.01) 
p=0.629 
1.00 (0.98, 
1.01) 
p=0.646 
1.00 (0.96, 
1.04) 
p=0.857 
1.00 (0.96, 
1.05) 
p=0.831 
1.00 (0.98, 
1.01) 
p=0.632 
0.99 (0.98, 
1.01) 
p=0.343 
1.00 (0.98, 
1.01) 
p=0.629 
NYHA class 
(NYHA I/II vs 
NYHA III/IV) 
0.91 (0.74, 
1.12) 
p=0.370 
0.90 (0.73, 
1.10) 
p=0.308 
0.89 (0.43, 
1.87) 
p=0.763 
0.79 (0.39, 
1.60) 
p=0.508 
0.81 (0.63, 
1.05) 
p=0.110 
0.87 (0.70, 
1.09) 
p=0.235 
0.91 (0.74, 
1.12) 
p=0.355 
HF aetiology 
(ischaemic vs 
non-
ischaemic) 
0.96 (0.71, 
1.31) 
p=0.810 
1.00 (0.82, 
1.22) 
p=0.988 
0.73 (0.39, 
1.39) 
p=0.340 
0.73 (0.40, 
1.31) 
p=0.284 
1.08 (0.84, 
1.38) 
p=0.562 
1.04 (0.84, 
1.29) 
p=0.723 
1.01 (0.83, 
1.24) 
p=0.910 
Ethnic group 
(white vs non-
white) 
1.02 (0.83, 
1.26) 
p=0.860 
1.02 (0.83, 
1.26) 
p=0.852 
1.02 (0.47, 
2.21) 
p=0.959 
1.06 (0.49, 
2.32) 
p=0.879 
1.14 (0.88, 
1.48) 
p=0.322 
1.06 (0.85, 
1.33) 
p=0.607 
1.02 (0.83, 
1.26) 
p=0.860 
Exercise 
capacity 
              
Peak VO2, 
directly 
measured* 
1.01 (0.99, 
1.04) 
p=0.259 
1.02 (0.99, 
1.04) 
p=0.234 
1.05 (0.95, 
1.16) 
p=0.352 
1.06 (0.96, 
1.17) 
p=0.262 
1.03 (0.99, 
1.06) 
p=0.124 
1.02 (0.99, 
1.04) 
p=0.243 
1.01 (0.99, 
1.04) 
p=0.259 
Peak VO2, 
directly 
measured and 
predicted* 
1.02 (0.99, 
1.04) 
p=0.153 
1.02 (0.99, 
1.04) 
p=0.134 
1.07 (0.98, 
1.17) 
p=0.125 
1.08 (0.99, 
1.17) 
p=0.078 
1.03 (1.00, 
1.06) 
p=0.057 
1.02 (0.99, 
1.05) 
p=0.129 
1.02 (0.99, 
1.04) 
p=0.153 
Standardised 
scores using 
peak VO2, 
6MWT, ISWT 
units and 
watts* 
1.09 (0.98, 
1.22) 
p=0.095 
1.10 (0.99, 
1.22) 
p=0.088 
1.30 (0.93, 
1.83) 
p=0.120 
1.32 (0.95, 
1.82) 
p=0.097 
1.16 (1.02, 
1.33) 
p=0.027 
1.11 (0.99, 
1.24) 
p=0.077 
1.09 (0.98, 
1.22) 
p=0.095 
*centered; peak VO2: peak oxygen uptake; ISWT: incremental shuttle walk test; 6MWT: 6-minute walk test. 
 
 
 
  
eTable 5. HF-specific hospitalisation - overall treatment effect and subgroups effects in studies included in IPD meta-
analysis 
 Primary 
analysis 
Secondary 
analysis 
Sensitivity analyses 
  Two-stage 
model,  
random effects 
HR (95% CI) 
p-value 
One-stage 
Cox model, 
stratified by 
study with 
fixed  
treatment 
effect 
HR (95% CI) 
p-value 
Two-stage model,  
random effects 
excluding  
HF-Action 
HR (95% CI) 
p-value 
 
One-stage 
Cox model, 
stratified by 
study with 
fixed  
treatment 
effect 
excluding  
HF-Action 
HR (95% CI) 
p-value 
Two-stage 
model,  
random 
effects 
1 year 
truncation 
HR (95% CI) 
p-value  
 
Two-stage 
model,  
random 
effects 
2 year 
truncation 
HR (95% 
CI) 
p-value  
Two-
stage 
model,  
random 
effects 
5 year 
truncatio
n 
HR (95% 
CI) 
p-value  
Overall effect 0.98 (0.71, 1.34) 
p=0.902 
0.94 (0.81, 
1.08) 
p=0.368 
1.00 (0.65, 1.54) 
p=0.999 
1.03 (0.79, 
1.35) 
p=0.829 
1.08 (0.88, 
1.33) 
p=0.470 
1.06 (0.83, 
1.34) 
p=0.658 
0.97 
(0.70, 
1.34) 
p=0.855 
Interaction terms 
Age (years)* 1.00 (0.99, 1.02) 
p=0.603 
1.00 (0.99, 
1.02) 
p=0.632 
1.00 (0.98, 1.03) 
p=0.958 
1.00 (0.97, 
1.02) 
p=0.906 
1.00 (0.99, 
1.02) 
p=0.640 
1.00 (0.99, 
1.02) 
p=0.611 
1.00 
(0.99, 
1.02) 
p=0.580 
Gender (male vs 
female) 
1.03 (0.73, 1.46) 
p=0.865 
0.99 (0.71, 
1.39) 
p=0.949 
0.70 (0.32, 1.53) 
p=0.372 
0.65 (0.33, 
1.29) 
p=0.215 
0.76 (0.46, 
1.24) 
p=0.274 
1.06 (0.68, 
1.66) 
p=0.803 
0.93 
(0.49, 
1.75) 
p=0.815 
Ejection fraction 
(%)* 
0.51 (0.14, 1.79) 
p=0.291 
0.99 (0.97, 
1.01) 
p=0.325 
0.99 (0.96, 1.03) 
p=0.540 
0.99 (0.97, 
1.01) 
p=0.350 
0.99 (0.97, 
1.02) 
p=0.569 
0.99 (0.97, 
1.01) 
p=0.350 
0.99 
(0.97, 
1.02) 
p=0.569 
NYHA class 
(NYHA I/II vs 
NYHA III/IV) 
1.55 (0.79, 3.02) 
p=0.200 
1.14 (0.84, 
1.54) 
p=0.399 
2.05 (0.86, 4.92) 
p=0.107 
1.74 (0.92, 
3.29) 
p=0.089 
0.81 (0.51, 
1.29) 
p=0.375 
1.17 (0.68, 
2.03) 
p=0.573 
1.21 
(0.72, 
2.04) 
p=0.475 
HF aetiology 
(ischaemic vs 
non-ischaemic) 
1.20 (0.64, 2.25) 
p=0.577 
1.28 (0.94, 
1.74) 
p=0.111 
0.95 (0.31, 2.95) 
p=0.928 
1.10 (0.57, 
2.16) 
p=0.771 
1.47 (0.94, 
2.29) 
p=0.128 
1.28 (0.90, 
1.84) 
p=0.172 
1.29 
(0.79, 
2.12) 
p=0.309 
Ethnic group 
(white vs non-
white) 
1.18 (0.85, 1.65) 
p=0.318 
1.19 (0.86, 
1.66) 
p=0.291 
† 1.79 (0.60, 
5.37) 
p=0.301 
1.25 (0.79, 
1.98) 
p=0.334 
1.20 (0.83, 
1.74) 
p=0.327 
1.18 
(0.85, 
1.65) 
p=0.318 
Exercise capacity 
PeakVO2, 
directly 
measured* 
0.97 (0.88, 1.07) 
p=0.538 
0.97 (0.93, 
1.01) 
p=0.149 
0.94 (0.80, 1.11) 
p=0.467 
0.98 (0.90, 
1.07) 
p=0.658 
0.99 (0.90, 
1.10) 
p=0.882 
0.99 (0.93, 
1.06) 
p=0.769 
0.98 
(0.89, 
1.08) 
p=0.685 
Peak VO2, 
directly 
measured and 
predicted* 
0.97 (0.89, 1.07) 
p=0.539 
0.97 (0.93, 
1.01) 
p=0.116 
0.95 (0.82, 1.10) 
p=0.483 
0.97 (0.89, 
1.05) 
p=0.424 
0.98 (0.92, 
1.05) 
p=0.610 
0.99 (0.94, 
1.03) 
p=0.535 
0.98 
(0.90, 
1.07) 
p=0.670 
Standardised 
scores using 
peak VO2, 
6MWT, ISWT 
units and watts* 
0.88 (0.62, 1.26) 
p=0.483 
0.86 (0.72, 
1.03) 
p=0.093 
0.83 (0.46, 1.49) 
p=0.527 
0.81 (0.56, 
1.16) 
p=0.246 
0.92 (0.69, 
1.23) 
p=0.576 
0.93 (0.75, 
1.16) 
p=0.517 
0.91 
(0.69, 
1.20) 
p=0.505 
*centered; †Study estimate not available as too few studies provide data; peak VO2: peak oxygen uptake; ISWT: incremental 
shuttle walk test; 6MWT: 6-minute walk test. 
eFigure 1. Funnel plots 
 
a. All-cause mortality       
Egger test -0.26, p=0.458                                                
 
 
b. HF-specific mortality  
Egger test -1.60, p=0.147 
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 c.  All-cause hospitalisation  
Egger test 0.16, p=0.739                                                             
 
 
d. HF-specific hospitalisation 
Egger test 0.32, p=0.610 
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